Ember Therapeutics Stock Performance
| EMBT Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Ember Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Ember Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental drivers, Ember Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Ember |
Ember Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.01 in Ember Therapeutics on November 28, 2024 and sell it today you would earn a total of 0.00 from holding Ember Therapeutics or generate 0.0% return on investment over 90 days. Ember Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Ember, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ember Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ember Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Ember Therapeutics, and traders can use it to determine the average amount a Ember Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EMBT |
Based on monthly moving average Ember Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ember Therapeutics by adding Ember Therapeutics to a well-diversified portfolio.
Ember Therapeutics Fundamentals Growth
Ember Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Ember Therapeutics, and Ember Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ember Pink Sheet performance.
| Current Valuation | 12 M | |||
| Shares Outstanding | 40 M | |||
| Price To Earning | 26.61 X | |||
| EBITDA | 9.4 M | |||
| Cash And Equivalents | 71.22 M | |||
| Cash Per Share | 0.41 X | |||
| Total Debt | 75 K | |||
| Debt To Equity | 0.33 % | |||
| Book Value Per Share | (0.74) X | |||
| Cash Flow From Operations | (16.72 K) | |||
| Total Asset | 184 | |||
| Retained Earnings | 289 K | |||
| Current Asset | 83.91 M | |||
| Current Liabilities | 25.3 M | |||
About Ember Therapeutics Performance
Assessing Ember Therapeutics' fundamental ratios provides investors with valuable insights into Ember Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Ember Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York. Ember Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Ember Therapeutics performance evaluation
Checking the ongoing alerts about Ember Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Ember Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ember Therapeutics generated a negative expected return over the last 90 days | |
| Ember Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (23.24 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ember Therapeutics currently holds about 71.22 M in cash with (16.72 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.412, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company shares are held by company insiders |
- Analyzing Ember Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ember Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Ember Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ember Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ember Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ember Therapeutics' pink sheet. These opinions can provide insight into Ember Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Ember Pink Sheet Analysis
When running Ember Therapeutics' price analysis, check to measure Ember Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ember Therapeutics is operating at the current time. Most of Ember Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ember Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ember Therapeutics' price. Additionally, you may evaluate how the addition of Ember Therapeutics to your portfolios can decrease your overall portfolio volatility.